Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Advances in multiple myeloma treatment have improved remission rates, necessitating sensitive minimal residual disease (MRD) detection.
• Multiparametric flow cytometry (MFC) is the primary method for MRD monitoring in bone marrow, with molecular detection also available.
• Standardized, highly sensitive approaches like 'next generation flow' enhance MFC's utility for MRD assessment.

Purpose of the Study:

• To review the application of MFC in MRD assessment for multiple myeloma.
• To discuss the technical aspects and clinical advantages of using MFC for MRD detection.
• To highlight the significance of MRD assessment in predicting patient outcomes.

Main Methods:

• Focus on multiparametric flow cytometry (MFC) for MRD detection.
• Review of technical protocols and sensitivity of MFC.
• Analysis of clinical data correlating MRD status with patient survival.

Main Results:

• MRD assessment, particularly MRD-negative status, is a stronger predictor of progression-free and overall survival than complete response achievement.
• Highly sensitive and reproducible MFC methods provide valuable prognostic information.
• The choice of MFC protocol significantly impacts the reliability of MRD assessment results.

Conclusions:

• MRD levels detected by MFC can serve as a biomarker for evaluating treatment efficacy in multiple myeloma.
• MFC-based MRD assessment can aid in treatment decision-making for multiple myeloma patients.
• MRD status determined by MFC may act as a surrogate for overall survival in multiple myeloma.